From: Post-trial follow-up methodology in large randomised controlled trials: a systematic review
1st author, year | Primary outcome for PTFU | RCT name (PTFU name) | No. years PTFUa | Intervention | No. randomised in-trial | No. at the start of PTFU | % participants lost in PTFU | Type of PTFU for primary outcome | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Post/Q | Clinic | Telephone | Data linkage | Paper records | Other | ||||||||
Alan, 2015 | Mortality | ProHOSP | 6 | CAP antibiotics | 1359 | 925 | 6 | Y | Y | ||||
Arbel, 2016 | Mortality | BIP | 20 | Bezafibrate | 3090 | 3090 | – | Y | |||||
Arber, 2011 | Cancer, safety | PreSAP | 2 | Celecoxib | 1561 | 1043 | 12 | Y | |||||
Avenell, 2012 | Mortality | RECORD | 3 | Vitamin D, Calcium | 5292 | 4394 | – | Y | |||||
Breitner, 2011 | Alzheimer’s disease | ADAPT | 2 | Naproxen, Celecoxib | 2528 | 2233 | 1 | Y | |||||
Bulbulia, 2011 | Mortality and morbidity | HPS | 6 | Simvastatin | 20,536 | 17519 | 0 | Y | Y | ||||
Cauley, 2013 | Hip fractures, cancers, CVE and mortality | WHI | 5 | Calcium plus vitamin D | 36,282 | 29862 | 1 | Y | |||||
Cherry, 2014 | Mortality, cancer | ESPIRIT | 12 | Oestrogen | 1017 | 1017 | – | Y | |||||
Chew, 2013 | Progression of age-related macular degeneration | AREDS | 5 | Antioxidants | 4757 | 3549 | – | Y | Y | Y | |||
Chowdhury, 2014 | Diabetes mellitus, mortality, MACE | ANBP2 | 7 | ACE inhibitor, Thiazide | 6083 | 5678 (6083 linked to death registry) | – | Y | Y | ||||
Cushman, 2012 | MACE, mortality | ALLHAT | 13 | Amlodipine, lisinopril | 32,804 | 17,722 (CVD), 27,755 (mortality) | – | Y | |||||
Dienstag, 2011 | Progression of Hep C | HALT-C | 4 | Peginterferon | 1050 | 743 | – | Y | |||||
Eastell, 2015 | Bone mineral density | HORIZON-PFT | 3 | Zoledronic acid | 7765 | 1223 | – | Y | Y | ||||
Ebbing, 2010 | Mortality | NORVIT, WENBIT | 4 | B vitamins | 6845 | 6261 | 0 | Y | |||||
Einstein, 2011 | Safety, immunogenicity | – | 2 | HPV vaccine | 1106 | 671 | 0 | Y | – | ||||
Erdmann, 2014 | Mortality, MI, stroke, MACE, (composite) | PROactive | 3 | Pioglitazone | 5238 | 3599 | 9 | Y | Y | Y | Y | ||
Ezzedine, 2010 | Skin cancer | SU.VI.MAX | 5 | Antioxidant vitamins | 12,741 | 11054 | 2 | Y | Y | ||||
Flossman, 2007 | Colorectal cancer | UK-TIA | 20 | Aspirin | 2449 | 2249 | – | Y | Y | ||||
Colorectal cancer | BDAT | 20 | Aspirin | 5139 | 5139 | – | Y | Y | |||||
Ford, 2016 | Mortality and morbidity | WOSCOPS | 20 | Pravastatin | 6595 | 5778 | – | Y | |||||
Gerstein, 2016 | MACE, mortality (composite) | ACCORD (ACCORDIAN) | 3 | Intensive glucose control | 10,251 | 8601 | – | Y | Y | ||||
Gluud, 2008 | Mortality | CLARICOR | 3 | Clarithromycin | 4373 | 4029 | 1 | Y | |||||
Gordon, 2012 | Efficacy and safety | REVEAL | 2 | Adalimumab | 1212 | 575 | 7 | Y | |||||
Grau, 2009 | Adenomas | AFPPS | 4 | Aspirin | 1121 | 1007 | 14 | Y | Y | ||||
Grubb, 2013 | Cancer | REDUCE | 2 | Dutasteride | 8231 | 2751 | – | Y | Y | ||||
Hackshaw, 2011 | Event-free survival | OVER 50S TRIAL | 10 | Tamoxifen | 3449 | 3449 | – | Y | |||||
Hague, 2016 | Mortality, cancer | LIPID | 10 | Pravastatin | 9014 | 7721 | 0 | Y | Y | Y | Y | Y | |
Hayashino, 2009 | Diabetes mellitus | PHI1 | 17 | Aspirin | 22,071 | 22,071 | – | Y | Y | ||||
Hayward, 2015 | MACE | VADT | 5 | Intensive glucose lowering vs standard therapy | 1791 | 1791 | 22 | Y | Y | ||||
Holman, 2008 | Macrovascular outcomes | UKPDS | 10 | Intensive glycaemic control | 3867 | 3277 | 20 | Y | Y | Y | |||
Hornslien, 2015 | Stroke, MI, mortality | SCAST | 3 | Candesartan | 2029 | 1286 | 2 | Y | |||||
Investigators, 2011 | Diabetes mellitus | DREAM (DREAM ON) | 2 | Rosiglitazone, ramipril | 5269 | 1653 | 18 | Y | |||||
Johnson, 2015 | Vaccine efficacy | SPS (LTPS) | 4 | Vaccine | 38,543 | 6867 | 6 | Y | Y | ||||
Jones, 2015 | Cancer, bone fractures | RECORD | 4 | Rosiglitazone | 4447 | 2546 | 1 | Y | Y | Y | |||
Kostis, 2011 | Mortality | SHEP | 13 | Chlorthalidone | 4736 | – | – | Y | |||||
Krane, 2016 | MACE, mortality (composite) | 4D | 8 | Atorvastatin | 1255 | 637 | 3 | Y | |||||
Lai, 2014 | Mortality, liver cancer | ATBC | 16 | α-tocopherol,β-carotene | 29,133 | 29105 | – | Y | |||||
Laterre, 2007 | Mortality | ADDRESS | 1 | Drotrecogin-α | 2640 | 2621 | 9 | Y | Y | Y | |||
Leslie, 2011 | Mortality | ENIGMA | 4 | Nitrous oxide | 2050 | 2002 | 17 | Y | Y | ||||
Leslie, 2015 | MACE, mortality | ENIGMA-II | 1 | Nitrous oxide | 7112 | 6651 | 12 | Y | Y | ||||
Lewis, 2011 | MACE | CAIFOS | 5 | Calcium | 1510 | 1510 | – | Y | |||||
Lloyd, 2013 | MACE, cancers, mortality | PROSPER | 3 | Pravastatin | 5804 | 5188 | – | Y | |||||
Menne, 2014 | Long-term micro, macrovascular benefit | ROADMAP (ROADMAP OFU) | 3 | Olmesartan medoxomil | 4449 | 2198 | 0 | Y | |||||
Ogihara, 2011 | MACE, cancer, mortality | CASE-J (CASE-J Ex) | 3 | Candesartan, amlodipine | 4728 | 2232 | 2 | Y | |||||
Radford, 2014 | Bone mineral density | Auckland Calcium Study | 5 | Calcium | 1471 | 1408 | 17 | Y | Y | ||||
Rothwell, 2010 | Colorectal cancer | Thrombosis Prev Trial, Swedish Aspirin Low Dose Trial, Dutch TIA Aspirin Trial, UK-Tia Aspirin Trial, British Doctors Aspirin Trial | 12, 13, 17, 18, 20 | Aspirin | 16,488 | 14033 | – | Y | Y | Y | |||
Tenkanen, 2006 | MACE, cancer, mortality | Helsinki Heart Study | 10 | Gemfibrozil | 4081 | 4081 | 0 | Y | Y | ||||
Wang, 2015 | Fracture incidence | NIT | 16 | Vitamins (14), minerals (12) | 3318 | 3318 | 1 | Y | Y | ||||
Weston, 2011 | Persistence of antibodies | 106316 | 3 | Vaccine dip, pert, tetanus | 2284 | 1505 | – | Y | |||||
Whiteley, 2014 | Disability | IST-3 | 1 | Alteplase | 3035 | 2348 | 2 | Y | |||||
Zoungas, 2014 | Mortality | ADVANCE (ADVANCE-ON) | 6 | Perindopril, indapamide | 11,140 | 8494 | – | Y | Y |